Targeted Disease(s):
COPD|Other

Purpose of Study:

A phase 2a randomized, placebo-controlled clinical study to evaluate the efficacy and safety of MK5475 in adults with pulmonary hypertension associated with Chronic Obstructive Pulmonary Disease.

Study Dates:
March 16, 2023 - September 15, 2026

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Lead Institution:
Merck & Co., Inc.

Funding Source:
Merck & Co., Inc.

Sponsors:

Merck & Co., Inc.

Contact:

Phone: 1-888-577-8839
Email: [email protected]
 

ClinicalTrails.gov Identifier:
NCT05612035

Register for Trial
Freedom From Smoking Clinic
, | May 29, 2024
Freedom From Smoking Clinic
Detroit, MI | May 29, 2024